Advanced Filters
noise

Oakland, California Clinical Trials

A listing of Oakland, California clinical trials actively recruiting patient volunteers.

Found 387 clinical trials
L Lora T Likova, PhD

Advanced Spatiomotor Rehabilitation for Navigation in Blindness & Visual Impairment

One of the most challenging tasks for blind and visually impaired individuals is navigation through a complex environment. The goal of the present multidisciplinary study is to increase spatial-cognition abilities in people who are blind or visually impaired through training with the previously-developed Cognitive-Kinesthetic Rehabilitation Training to improve navigation, and …

18 - 80 years of age All Phase N/A
M Megan McLaughlin, MD, MPH

Text Education About Cardiovascular Health and HIV (TEACH-HIV)

The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).

40 years of age All Phase N/A
Y Yingxin Jia, PhD

Medial-prefrontal Enhancement During Schizophrenia Systems Imaging

This randomized controlled trial in healthy controls (HC) and patients with schizophrenia (SZ) aims to examine 1) the underlying cognitive and neural cause of self-agency deficits in SZ; 2) the responsiveness to a novel navigated repetitive transcranial magnetic stimulation (nrTMS) target in the medial/superior prefrontal cortex (mPFC); and 3) how …

18 - 64 years of age All Phase N/A
R Rita Mehta, MD

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer

This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of …

18 years of age Male Phase 2
J Janice Scudmore, NP

Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)

Despite advances in prenatal diagnosis and postnatal therapies, including ECMO (Extracorporeal Membrane Oxygenation), inhaled nitric oxide therapy, and ventilator strategies that minimize ventilator-induced lung injury, morbidity and mortality rates for babies with severe CDH remain high. The rationale for fetal therapy in severe CDH is to promote adequate lung growth …

18 years of age Female Phase N/A
C Cancer Clinical Trials Team

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of …

12 - 30 years of age All Phase 1/2

The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots

Open labelled, virtual home based study to assess the test repeatability and the failure/rejection rate of the samples collected at home by participants.

18 - 80 years of age All Phase N/A
M Michel Shami, MD

Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM

Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20/40 or worse. However, it is …

50 years of age All Phase N/A

A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing

This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing

6 - 72 years of age All Phase 2
A Aaron White

Neuroblastoma Maintenance Therapy Trial

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 …

1 - 30 years of age All Phase 2

Simplify language using AI